company background image
TNGX logo

Tango Therapeutics NasdaqGM:TNGX Stock Report

Last Price

US$7.70

Market Cap

US$821.7m

7D

-9.4%

1Y

91.5%

Updated

27 Mar, 2024

Data

Company Financials +

Tango Therapeutics, Inc.

NasdaqGM:TNGX Stock Report

Market Cap: US$821.7m

Tango Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tango Therapeutics
Historical stock prices
Current Share PriceUS$7.70
52 Week HighUS$13.03
52 Week LowUS$2.47
Beta0.90
1 Month Change-32.28%
3 Month Change-25.60%
1 Year Change91.54%
3 Year Change-30.76%
5 Year Changen/a
Change since IPO-24.73%

Recent News & Updates

Recent updates

Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Mar 19
Risks Still Elevated At These Prices As Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Dive 30%

Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Mar 06
Tango Therapeutics (NASDAQ:TNGX) Is In A Good Position To Deliver On Growth Plans

Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Jan 08
Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Share Price Could Signal Some Risk

Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

Nov 09
Industry Analysts Just Upgraded Their Tango Therapeutics, Inc. (NASDAQ:TNGX) Revenue Forecasts By 15%

New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Aug 12
New Forecasts: Here's What Analysts Think The Future Holds For Tango Therapeutics, Inc. (NASDAQ:TNGX)

Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

May 10
Will Tango Therapeutics (NASDAQ:TNGX) Spend Its Cash Wisely?

Tango Therapeutics started at buy at Wainwright on synthetically lethal targets for cancer

Oct 20

Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Oct 05
Companies Like Tango Therapeutics (NASDAQ:TNGX) Are In A Position To Invest In Growth

Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 13
Tango Therapeutics, Inc. (NASDAQ:TNGX) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Tango Therapeutics GAAP EPS of -$0.28 beats by $0.03, revenue of $5.78M beats by $0.12M

Aug 10

We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

May 28
We're Not Worried About Tango Therapeutics' (NASDAQ:TNGX) Cash Burn

We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Jan 06
We're Interested To See How Tango Therapeutics (NASDAQ:TNGX) Uses Its Cash Hoard To Grow

Shareholder Returns

TNGXUS BiotechsUS Market
7D-9.4%0.9%0.4%
1Y91.5%10.3%28.8%

Return vs Industry: TNGX exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: TNGX exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is TNGX's price volatile compared to industry and market?
TNGX volatility
TNGX Average Weekly Movement9.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TNGX's share price has been volatile over the past 3 months.

Volatility Over Time: TNGX's weekly volatility has decreased from 19% to 9% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017140Barbara Weberhttps://www.tangotx.com

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers.

Tango Therapeutics, Inc. Fundamentals Summary

How do Tango Therapeutics's earnings and revenue compare to its market cap?
TNGX fundamental statistics
Market capUS$821.73m
Earnings (TTM)-US$101.74m
Revenue (TTM)US$36.53m

22.5x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNGX income statement (TTM)
RevenueUS$36.53m
Cost of RevenueUS$115.20m
Gross Profit-US$78.67m
Other ExpensesUS$23.07m
Earnings-US$101.74m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin-215.38%
Net Profit Margin-278.54%
Debt/Equity Ratio0%

How did TNGX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.